Influenza Epidemiology and Vaccine Effectiveness Following Funded Influenza Vaccine in Queensland, Australia, 2022
Influenza and Other Respiratory Viruses·
- DOI
- 10.1111/irv.70007
- PMID
- —
- PMCID
- —
- OpenAlex
- W4402840920
- Study type
- Journal article
- Publisher
- Wiley
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The article provides Queensland-specific evidence on influenza activity and vaccine effectiveness during a year when vaccination was publicly funded for all residents. It also reports outcome-specific and age-specific effectiveness estimates, including estimates for hospitalisation.
Structured evidence summary
Research question
The study examined how influenza epidemiology in Queensland in 2022 compared with 2017–2021 and estimated influenza vaccine effectiveness during 2022.
Study design
The study combined descriptive analysis of laboratory-confirmed influenza notifications with a case-control analysis of vaccine effectiveness. Cases and controls were matched by age, postcode, and specimen collection date, with regression adjustment for sex; a separate matched analysis assessed effectiveness against hospitalisation.
Population and setting
The setting was Queensland, Australia, during 2022. The analysis included laboratory-confirmed influenza notifications, individuals who tested negative for COVID-19 as controls, and hospitalised influenza cases in the hospitalisation analysis.
Main findings
Queensland's 2022 influenza season began earlier than in the preceding five years and included 45,311 cases, exceeding the earlier annual average reported by the study. Adjusted vaccine effectiveness was 39% against laboratory-confirmed influenza and 54% against influenza-related hospitalisation, with estimates varying by age; among children younger than 9 years, effectiveness was higher for those completing the dose schedule.
Public-health relevance
The article provides Queensland-specific evidence on influenza activity and vaccine effectiveness during a year when vaccination was publicly funded for all residents. It also reports outcome-specific and age-specific effectiveness estimates, including estimates for hospitalisation.
Important limitations
The supplied evidence does not provide an explicit limitations section. This summary is limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade assessment of bias, representativeness, confounding, and analytic limitations.
GIDS interpretation
The article is discoverable as Queensland, Australia evidence on influenza vaccination and vaccine effectiveness, with relevance to 2022 influenza epidemiology. It provides context for literature review only and does not establish or confirm any live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.